Today, androgen deprivation therapy (ADT) using gonadotropin-releasing hormone (GnRH) agonists is widely used for prostate cancer patients with metastatic, locally invasive, or high-risk localised disease [1, 2]. This evidence concerns the gene GNRH1 and prostate carcinoma.